je.st
news
Tag: trial
KPN launches nationwide trial for 4G call, video calls
2015-09-29 09:17:00| Telecompaper Headlines
(Telecompaper) KPN has started a nationwide trial for calling over 4G. It expects to introduce the technology to customers next year. Up to now, 4G had only been used for data traffic. KPN is also testing 4G video calling with the technology, so that customers can switch during a call to a video call. The Dutch incumbent is looking at different types of handsets. It expects the number of users with a 4G phone to increase sharply over the coming months. KPN believes 4G will become the new standard for telephony. Around 3 million KPN customers currently use the operator's 4G network.
SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA
2015-09-28 14:00:56| Merck.com - Product News
Dateline City: WALTHAM, Mass. and KENILWORTH, N.J. Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma WALTHAM, Mass. and KENILWORTH, N.J. Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndaxs entinostat in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. Language: English read more
New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
2015-09-27 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the companys anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
range
types
presented
Novo Nordisk successfully completes diabetes drug phase 3a trial
2015-09-26 03:39:15| Biotech - Topix.net
Danish pharmaceutical company Novo Nordisk has successfully completed the second phase 3a trial with its diabetes drug semaglutide, it said on Friday.
Tags: trial
drug
phase
successfully
Amgen, Allergan Biosimilar Avastin Hits In Trial
2015-09-24 17:07:51| Biotech - Topix.net
Amgen and Allergan, which started their collaboration back in 2011 when Allergan was a generic drug maker called Watson Pharmaceuticals, released few details but said the drug ABP 215 had shown clinical equivalence to Avastin as measured by tumor shrinkage, duration of response and progression-free survival. Launched in 2004, Avastin is drawing $7 billion for Roche as a treatment for a variety of different cancers, about 20% to 25% of it from lung cancer.
Tags: trial
hits
amgen
allergan
Sites : [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] next »